Amgen Inc (AMGN)

163.06
1.65 1.00
NASDAQ : Health Care
Prev Close 164.71
Open 164.47
Day Low/High 162.94 / 165.22
52 Wk Low/High 130.09 / 181.81
Volume 4.07M
Avg Volume 4.11M
Exchange NASDAQ
Shares Outstanding 736.45M
Market Cap 121.45B
EPS 10.30
P/E Ratio 16.10
Div & Yield 4.60 (2.80%)

Latest News

Amgen Awards Three Golden Tickets For LabCentral Residency

Amgen Awards Three Golden Tickets For LabCentral Residency

Innovative Start-Up Companies Receive One-Year Free Lab Space

European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

First Biosimilar Adalimumab Approved in the European Union

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Get your plan in place, but understand that the Republic is not in jeopardy.

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

Obamacare? Trumpcare? These stocks don't care.

These 4 Healthcare Charts Are Signaling Buys

These 4 Healthcare Charts Are Signaling Buys

Here's a rundown of four technical setups that are showing solid trading potential.

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Slow Day for the Market; Adobe Builds Next Step in Tech Surge: Jim Cramer's View

Slow Day for the Market; Adobe Builds Next Step in Tech Surge: Jim Cramer's View

Cramer shares his views on how the market had a slow, pre-Trump kind of day, and also discusses the next step in Adobe's tech surge.

Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients

Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients

Results From Two Studies Show Approximately 80 Percent of Prescription Claims in the U.S. Are Initially Rejected

Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study

Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study

Repatha Cognitive Function Trial Evaluated Subset of Patients From Cardiovascular Outcomes Trial

How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More

How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More

Here's how to trade six of the most active names on the market this past week.

Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis

Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis

Wall Street ends with modest gains in a week in which the Federal Reserve decided to pull the trigger on an interest rate hike.

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Wall Street ends a jampacked week little changed as a selloff in health care stocks counters broad gains elsewhere.

Closing Bell: Citi Dumps SeaWorld; U.S. Stocks Churn as Health Care Falls

Closing Bell: Citi Dumps SeaWorld; U.S. Stocks Churn as Health Care Falls

Stocks churn around the flatline to end the week as a selloff in health care counters gains seen elsewhere.

Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report

Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report

Fired former U.S. Attorney Preet Bharara was investigating stock trades made by Health and Human Services Secretary Tom Price, according to one report.

Cramer: Nothing to See in This Market, Move Along

Cramer: Nothing to See in This Market, Move Along

Today's session is reminiscent of a pre-Trump day.

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Stocks rise on Friday even as a selloff in health care extends into its second day.

Be Patient With Amgen After Its Major Breakdown

Be Patient With Amgen After Its Major Breakdown

More downside is ahead for Amgen following Friday morning's huge breakdown gap.

Midday Report: Amgen Leads Health Care Lower; U.S. Stocks Fall

Midday Report: Amgen Leads Health Care Lower; U.S. Stocks Fall

Stocks creep lower on Friday as a selloff in health care extends into its second day, this time led by Amgen shares.

Jim Cramer Discusses Adobe, Amgen, Canada Goose, Costco and Starbucks

Jim Cramer Discusses Adobe, Amgen, Canada Goose, Costco and Starbucks

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer discusses Friday's most talked about stocks including Adobe Systems, Amgen, Canada Goose, Costco and Starbucks.

AveXis, Esperion and Amgen Among Biotech Movers

AveXis, Esperion and Amgen Among Biotech Movers

AveXis, Esperion Therapeutics, Medicines Co. and Amgen were among the biotech stock movers Friday morning.

Jim Cramer: I Don't Want to Give Up On Amgen

Jim Cramer: I Don't Want to Give Up On Amgen

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer doesn't want to give up on Amgen.

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks creep lower on Friday as a selloff in health care extends into its second day.

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?

This Key Measure Shows the S&P Could Be Headed for a 5% Pullback

This Key Measure Shows the S&P Could Be Headed for a 5% Pullback

Oil and natural gas prices are on the downswing and one key measure seems to pointing that we could be nearing a pullback in the S&P.

Is Amgen's Cholesterol Drug Repatha Worth Its Hefty Price Tag?

Is Amgen's Cholesterol Drug Repatha Worth Its Hefty Price Tag?

Repatha costs $14,000 per year before discounts.

Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues

Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues

Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Investor sentiment soured on Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.